Abstract
The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Current Pharmaceutical Biotechnology
Title: Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009)
Volume: 10 Issue: 8
Author(s): Leyre Zuniga and Begona Calvo
Affiliation:
Abstract: The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Export Options
About this article
Cite this article as:
Zuniga Leyre and Calvo Begona, Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009), Current Pharmaceutical Biotechnology 2009; 10 (8) . https://dx.doi.org/10.2174/138920109789978702
DOI https://dx.doi.org/10.2174/138920109789978702 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets The Protective Effects of Lupine (<i>Lupinus albus</i>) Fruit Extract Against to Destructive Effects of Hyperglycemia in Type I Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Decreasing Arterial Aging by Controlling Blood Pressure Levels and Hypertension: A Step Forward
Current Vascular Pharmacology Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Current Pharmaceutical Design Signal Transduction of Steroidogenic Hormones to the Adrenal and Gonadal Mitochondria and the Possibilities for Combating Lipoid Congenital Adrenal Hyperplasia
Current Signal Transduction Therapy Role of AMP-Activated Protein Kinase in the Control of Glucose Homeostasis
Current Molecular Medicine Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets How Insulin Receptor Substrate Proteins Regulate the Metabolic Capacity of the Liver - Implications for Health and Disease
Current Medicinal Chemistry Immunomodulatory Effect of Cytokines in the Differentiation of Mesenchymal Stem Cells: A Review
Current Stem Cell Research & Therapy Potential Inhibitors of Protein Tyrosine Phosphatase (PTP1B) Enzyme: Promising Target for Type-II Diabetes Mellitus
Current Topics in Medicinal Chemistry Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Current Drug Targets Recent Patents Regarding Essential Oils and the Significance of their Constituents in Human Health and Treatment
Recent Patents on Anti-Infective Drug Discovery Ethosomes and its Applications in Transdermal Drug Delivery
Current Drug Therapy Modulation of Cytokine Network in the Comorbidity of Schizophrenia and Tuberculosis
Current Topics in Medicinal Chemistry Acute Exercise Testing of COPD Patients: The Effect on Systemic Inflammatory Proteins
Current Respiratory Medicine Reviews Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding
Current Neuropharmacology Glycogen Phosphorylase Inhibitors
Mini-Reviews in Medicinal Chemistry Does Pregnancy Affect the Metabolic Equivalent at Rest and During Low Intensity Exercise?
Current Women`s Health Reviews